Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
ST. LOUIS, Feb. 16, 2016 -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that William C. Mills, CEO, and Martin C. Stammer, CFO, will participate in BTIG’s 2016 MedTech Conference on Thursday, February 25, 2016.
The conference is being held from February 24-26, 2016 at The Cliff Lodge Hotel in Snowbird, Utah, and consists of a full day of one-on-one meetings.
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
Press Contact: Martin Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 [email protected]
